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ABSTRACT
Background/aims: Five nucleoside/nucleotide treatments are now avail-
able for chronic hepatitis B (CHB). This meta-analysis aimed to assess the
relative efﬁcacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir
disoproxil fumarate (TDF), and nucleos(t)ide combinations in the treat-
ment of CHB.
Methods: A systematic review of MEDLINE and the Cochrane library
was conducted to identify all studies evaluating these nucleos(t)ides in
adults with CHB. Randomized controlled trials were included in the
meta-analysis if they reported the proportion of patients with undetectable
hepatitis B virus (HBV) DNA or hepatitis B e antigen (HBeAg) loss/
seroconversion at 1 year. Bayesian mixed treatment comparison meta-
analyses were conducted in WinBUGS to assess relative efﬁcacy.
Results: A random-effects meta-analysis of trials on treatment-naive
patients with HBeAg-positive CHB demonstrated that 94% of patients
will achieve HBV DNA < 300 copies/ml after 1 year with TDF, compared
with 73% for entecavir, 50% for adefovir, and 38% for lamivudine. There
was a 97.7% probability that TDF enabled a greater proportion of
patients to achieve HBV DNA < 300 copies/ml at 1 year than all other
treatments considered in the analysis. TDF was signiﬁcantly superior to all
nucleos(t)ides for this outcome at the 0.05 level. There were no statistically
signiﬁcant differences between nucleos(t)ides in HBeAg seroconversion at
1 year, based on a ﬁxed-effects meta-analysis in the same population. More
trials on HBeAg-negative and drug-resistant patients are required to facili-
tate meta-analyses for these subgroups.
Conclusions: In nucleos(t)ide-naive patients with HBeAg-positive CHB,
TDF is associated with the highest probability of achieving undetectable
HBV DNA at 1 year of all nucleos(t)ides considered.
Keywords: hepatitis B, indirect comparison, mixed treatment comparison
meta-analysis, multiple treatment meta-analysis, network meta-analysis,
systematic review, viral hepatitis.
Introduction
Chronic hepatitis B (CHB) comprises liver inﬂammation and
damage caused by the hepatitis B virus (HBV), which can lead to
cirrhosis and hepatocellular carcinoma [1]. Eight drugs are now
licensed in the UK for use in CHB: the nucleosides entecavir
(ETV), lamivudine (LAM) and telbivudine (LdT); the nucleotides
adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate
(TDF); and peginterferon-alpha-2a, interferon-alpha-2a and
interferon-alpha-2b [2].
Although numerous trials have evaluated the efﬁcacy of the
three newest agents (ETV, LdT, and TDF) compared with LAM
or ADV [3–10], no head-to-head randomized controlled trials
(RCTs) have yet compared ETV, LdT, and TDF directly. Esti-
mates of relative efﬁcacy are required to inform clinical decisions
about patient management, national and local treatment guide-
lines, and economic evaluations assessing the cost-effectiveness of
the different treatment options.
A previous meta-analysis pooled the results of studies evalu-
ating ADV, ETV, LAM, and placebo [11] and concluded that
ETV was superior to both ADV and LAM. However, the analysis
was primarily based on the absolute effects observed in indi-
vidual arms of different trials [11] and therefore did not take
account of the relative treatment effects observed in each study.
Furthermore, the analysis did not assess the efﬁcacy of LdT or
TDF or include studies published since 2004.
Standard meta-analytical techniques evaluate the relative efﬁ-
cacy of one treatment compared with a single comparator [12].
However, mixed treatment comparison (MTC) methods have
recently been developed that estimate the relative efﬁcacy of any
number of different treatments by taking account of the entire
network of RCT evidence [12–15]. MTC is also known as
network meta-analysis and multiple-treatments meta-analysis
and is now recommended by the National Institute for Health
and Clinical Excellence (NICE) [16].
We set out to use MTC to assess the relative efﬁcacy of the
following nucleos(t)ides in the treatment of CHB in terms of
achieving viral suppression and seroconversion: ADV; ETV;
LAM; LdT; TDF; placebo; and combinations of these drugs.
Methods
Systematic Review
MEDLINE/PubMed and the Cochrane library were searched on
August 31, 2007; additional studies were identiﬁed through
manufacturer/conference websites and citations within published
review articles.
The systematic review used broad, prespeciﬁed inclusion cri-
teria to identify all relevant studies evaluating nucleos(t)ides in
the treatment of CHB; these inclusion criteria are available on
request. The wider review included nonrandomized studies as
well as RCTs on diverse populations in order to provide data
inputs for a model-based economic evaluation [17] as well as
identifying RCTs for meta-analysis.
Studies identiﬁed in the systematic review were considered for
meta-analysis if they met the inclusion criteria shown in Table 1.
Meta-analyses were planned on four patient subgroups:
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nucleos(t)ide-naive patients with 1) hepatitis B e antigen
(HBeAg)-positive or 2) HBeAg-negative CHB; and patients who
were resistant/refractory to one or more nucleos(t)ides at baseline
with 3) HBeAg-positive or 4) HBeAg-negative CHB. However,
this article focuses on the results of analyses on HBeAg-positive
nucleos(t)ide-naive patients.
Data Extraction
Data were extracted from journal articles, study reports, confer-
ence abstracts, summaries of product characteristics and (where
available) clinical study reports. Data were extracted by one
researcher and all data used in the meta-analysis were checked
against the original sources by two other researchers. Any typos
or discrepancies between the extracted data and the source mate-
rial were resolved through reference to the original sources.
Data were extracted on the number/proportion of patients
with HBeAg loss, HBeAg seroconversion, and HBV DNA levels
undetectable by polymerase chain reaction (PCR) after 1 year of
treatment (range: 40–72 weeks). In cases where no available data
source reported the number of patients meeting a particular end
point, patient numbers were calculated from percentages and
were not rounded. All outcomes were recorded as reported by the
trial, whether intent-to-treat or per protocol in order to maxi-
mize the amount of data available for the meta-analysis;
however, all but two trials included in the analysis of HBeAg-
positive CHB presented intent-to-treat data (Table 2).
Allowance for Missing Data
Meta-analyses were conducted on two outcomes: the probability
of HBeAg seroconversion and the probability of achieving HBV
DNA < 300 copies/ml after 1 year’s treatment. These outcomes
were chosen to provide transition probabilities for a model-based
economic evaluation [17]. A threshold of 300 copies/ml was used
because this is the threshold most commonly reported in trials
using PCR. Because a wide range of HBV DNA thresholds have
been used in the literature and as some studies report HBeAg loss
but not HBeAg seroconversion, statistical transformations were
used to estimate these parameters from data on closely related
outcome measures so that all available data could be meta-
analyzed. Combining data on different outcomes without making
appropriate adjustments could introduce bias into the analysis; in
particular, because two studies observed that no placebo-treated
patients achieved HBV DNA < 400 copies/ml [18,19], combining
data on different thresholds without adjusting for this is likely to
have biased analyses in favor of TDF and ADV.
Data on the number of patients with HBeAg loss were con-
verted into estimates of the number undergoing HBeAg serocon-
version by assuming that 92% of patients losing HBeAg will also
Table 1 Summary of inclusion and exclusion criteria for the meta-analysis
Study design Only randomized controlled trials were included.
Subjects Studies were only included if:
The entire study population was chronically infected with HBV, or if results for a subgroup of patients with CHB were reported
separately.
<50% of patients had HIV coinfection, because HIV coinfected patients are likely to have a different probability of response than
mono-infected patients [1,61]. In practice however, all trials meeting inclusion criteria excluded patients with HIV.
Studies were excluded if they exclusively recruited:
Children (<18 years), because nucleos(t)ides are licensed only for adults [2].
Pregnant women, pre-, post- or peri-transplant patients or patients with decompensated cirrhosis, cancer, or inactive liver disease.
Intervention Studies were only included if they evaluated 1 of the following treatments:
245 mg/day tenofovir disoproxil (as fumarate), which is equivalent to 300 mg/day tenofovir disoproxil fumarate (TDF)
10 mg/day adefovir dipivoxil (ADV)
0.5 mg/day or 1 mg/day entecavir (ETV)
600 mg/day telbivudine (LdT)
100 mg/day lamivudine (LAM)
Any combination of these treatments
The doses considered comprise all those licensed in the UK for CHB.
Study arms evaluating interferon-alpha or peginterferon-alpha, unlicensed treatments/doses (other than placebo) or sequential use of
several treatments within the same 12-month period were excluded from the analysis.Any study that had <2 treatment arms after
exclusion of any arms using interferons or unlicensed therapies was also excluded from the meta-analysis. Interferons were excluded
because they were outside the scope of the analysis and as the outcomes of interferon therapy are most appropriately assessed 24
weeks after discontinuation of therapy, which is not the case for nucleos(t)ides. Furthermore, the efﬁcacy of interferons is affected
by race, age, sex, viral genotype, and baseline viral load and ALT [1,62], whereas nucleos(t)ides suppress HBV DNA effectively across
patient groups [1,62]; subsequently, including interferons would have introduced additional heterogeneity not applicable to
nucleos(t)ides.Additionally, consideration of the wide range of formulations, doses and dosing frequencies or durations that are
available for interferons would have complicated the analysis substantially.
Outcome measures Trials were only included if they reported 1 of the below outcomes after 40–72 weeks of therapy:
Percentage/number of patients with HBV DNA levels below a threshold of 1000 copies/ml or less. Studies exclusively using higher
thresholds were excluded as these are generally based on older assays, such as bDNA or hybrid capture techniques (LLQ
1.4 ¥ 105–0.7 ¥ 106 copies/ml) rather than PCR techniques (LLQ 20–1000 copies/ml) [63–65].
Percentage/number of patients with HBeAg seroconversion or loss.
Date of publication No limits on date of publication were used, although searches for studies on adefovir and lamivudine were limited to those published
since July 1, 2004 as earlier studies were identiﬁed from previous systematic reviews [66,67].
Language of publication Inclusion was not limited to published trials. Language limited inclusion only if no English translation was available from the British
Library.
Subgroups considered Trials were only included in the meta-analysis of nucleos(t)ide-naive HBeAg-positive patients if (a) >66.7% of patients were
HBeAg-positive or if results for an HBeAg-positive subgroup were reported separately and (b) <33.3% of patients were resistant to,
failed to respond to or relapsed after initially responding to treatment with lamivudine or 1 of the nucleos(t)ides considered in
the trial.
Trials on 3 other patient populations were considered for meta-analysis, although results are not presented in this article:
Predominantly (>66.7%) HBeAg-negative and <33.3% treatment-refractory.
Predominantly (>66.7%) HBeAg-positive and >66.7% lamivudine-refractory.
Predominantly (>66.7%) HBeAg-negative and >66.7% lamivudine-refractory.
CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HIV, human immunodeﬁciency virus; LLQ, lower limit of quantiﬁcation; PCR, polymerase chain reaction.
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undergo HBeAg seroconversion within the same year, based on
data extracted from the three largest trials reporting both mea-
sures, where the ratio of seroconversion to loss ranged from 88%
to 100% [3,20,21].
Data on the proportion of patients in the two main TDF trials
[9,10,21,22] who had HBV DNA below one of four different
thresholds (169, 300, 400, and 1000 copies/ml) were used to
estimate a statistical model to predict the number of patients with
HBV DNA levels < 300 copies/ml from the number of patients
meeting other HBV DNA targets (details available on request).
The model ﬁtting the data best (R2 = 0.7554) was
n N n N ThresholdX
ThresholdY
Y X= ( ) − ( ) +[
( )]
0 0538
0 0538
. ln
. ln (1)
where
• ThresholdX = threshold HBV DNA level (in copies/ml) for
which data are available; if data on several thresholds are
available, the threshold closest to ThresholdY should be
used;
• nX = the number of patients in this trial with HBV DNA
below ThresholdX;
• nY = the number of patients in this trial with HBV DNA
below ThresholdY;
• N = total number of patients with HBV DNA measure-
ments;
• ThresholdY = threshold HBV DNA level of interest (in
copies/ml).
This equation was validated against data from the BEHOLD
AI463022 trial [3] and was used to estimate the number of
patients with HBV DNA < 300 copies/ml for use in the meta-
analysis in cases where trials used other thresholds. In cases
where the equation predicted negative numbers (for example if
no patients had HBV DNA < 400 copies/ml), it was assumed that
no patients would have HBV DNA < 300 copies/ml. Equation 1
may also be used for other purposes where it is necessary to
convert between HBV DNA thresholds between 169 and 1000
copies/ml.
Statistical Methods
The techniques of Bayesian MTC meta-analysis [12,13,15] were
used to assess the relative efﬁcacy of the nucleos(t)ides. MTC
techniques allow all evidence to be taken into account, whether
direct (from head-to-head RCTs) or indirect (calculated from
trials with common comparators). These methods use the prin-
ciples underpinning standard indirect comparisons [23,24] and
are based on relative treatment effects (in this case the natural log
of the odds ratio, log-OR) in order to preserve trial randomiza-
tion and minimize bias.
MTC was conducted using WinBUGS Version 1.4 (MRC
Biostatistics Unit, Cambridge, UK) [25], which uses Bayesian
Markov chain Monte Carlo Gibbs sampling methods to ﬁt user-
deﬁned models. We used statistical models for ﬁxed and random-
effects MTC analyses that were developed by Bristol University
and allow for trials with up to three treatment arms [13,14,26,27].
The code used is available at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i8_Fidler.asp.
As with all meta-analyses, MTC may be conducted using
either ﬁxed or random-effects models. Random-effects models
allow for the possibility that the true treatment effect may differ
between trials [12]. We used random-effects models when there
was evidence of heterogeneity or when ﬁxed-effects models ﬁtted
the data poorly. Model ﬁt was assessed based on residual devi-
ance [28] and deviance information criteria (DIC) [25].
LAM was used as the baseline drug because it has been
evaluated in the largest number of RCTs. The absolute probabil-
ity of responding to LAM was based on the crude average prob-
ability of response across the LAM arms of all trials evaluating
this treatment; the probability of responding to other treatments
was calculated from this ﬁgure and the log-ORs for each treat-
ment relative to LAM.
Differences between treatments were considered signiﬁcantly
signiﬁcant at the 0.05 level if the 95% credible (Bayesian prob-
ability) interval (CrI) for the log-OR did not cross zero. We also
calculated the probability that each treatment was best based on
the proportion of Markov chain iterations in which that treat-
ment had the highest probability of viral suppression/HBeAg
seroconversion. All P-values represent Bayesian P-values. Treat-
ment effects based on head-to-head trials were estimated using
pair wise frequentist meta-analyses conducted in Stata Version
10.0 (StataCorp, College Station, TX) using the metan
command; the same methods were used to calculate the odds
ratio for viral suppression in HBeAg-negative patients compared
with HBeAg-positive patients.
The impact of using ﬁxed and random-effects models, alter-
native priors, adding/removing trials and making no adjustment
for HBV DNA threshold was evaluated in sensitivity analyses.
In common with previous research [13,27,29,30], non-
informative prior distributions were used for all treatment effects
and the odds of responding to LAM to ensure that the results
were primarily driven by the data; see code for more details:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Fidler.asp. However, sensitivity analyses suggested that
the posterior estimates of the uncertainty around treatment
effects (but not the posterior means) were sensitive to the priors
used. Informative half-normal priors [31] were therefore used for
the between-studies SD in order to allow this external data to
help inform the between-studies SD; these distributions were
based on a meta-analysis of interferon trials identiﬁed in a pub-
lished systematic review [32]. The methods used to estimate these
priors are described in more detail at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i8_Fidler.asp.
Although reasonable convergence was achieved after a
burn-in of 100,000 simulations, between 500,000 and 925,000
burn-in simulations were conducted for the main analyses to
ensure that robust results were generated. For all analyses, results
were based on a further 20,000 sampled simulations of two
chains using different initial values.
Additional details of the methods used, data on model ﬁt or
convergence and results of sensitivity analyses are available from
the authors on request.
Results
Studies Identiﬁed
Of the 1272 publications identiﬁed through electronic searches,
77 RCTs and 46 nonrandomized studies met the inclusion crite-
ria for the wider systematic review (Fig. 1); details available from
the authors on request. For the purposes of this analysis, the
HBeAg-positive and HBeAg-negative subgroups of the GLOBE
trial comparing LdT and LAM [33] were counted as two separate
studies.
Twenty-three RCTs met the narrower inclusion criteria for
the meta-analysis [3–6,8–10,18,19,33–49]. Thirteen studies
were included in the analysis of treatment-naive patients with
HBeAg-positive CHB [3–6,8,9,18,33–38], four were on
treatment-naive HBeAg-negative CHB [10,19,33,39], ﬁve were
on LAM-refractory patients with HBeAg-positive CHB
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[40–48], and one was on LAM-refractory HBeAg-negative
CHB [49] (Fig. 2).
HBeAg-Positive Treatment-Naive Patients
Thirteen trials met the inclusion criteria for the analysis of
HBeAg-positive, treatment-naive patients. The trials used similar
methods and comparable patient populations (Table 2), although
one recruited patients with hepatitis D virus coinfection [38] and
one used an older, less sensitive, PCR assay to measure viral load
[37].
Ten studies [3–6,8,9,18,33,36,37] on HBeAg-positive
treatment-naive patients reported the proportion of patients with
undetectable HBV DNA by PCR after 1 year of therapy.
Although model ﬁt was similar for ﬁxed and random-effects
models (DIC = 141–144), a random-effects model was used to
meta-analyze data on this outcome as there was evidence of
heterogeneity (between-studies SD: 0.470 [95% conﬁdence inter-
val (CI) 0.026–1.166]).
In this analysis, TDF had a signiﬁcantly higher probability of
undetectable HBV DNA at 1 year than any other nucleos(t)ide
considered in the analysis (P < 0.05; Tables 3 and 4, Fig. 3).
There was found to be a 97.7% probability that TDF enabled a
greater proportion of patients to achieve HBV DNA < 300
copies/ml than all other treatments considered in the analysis
(Table 4). All nucleos(t)ide therapies and combinations were
found to be signiﬁcantly more effective than placebo for this
outcome and ETV, LdT, and TDF were also signiﬁcantly more
effective than LAM (P < 0.05; Table 3). Sensitivity analyses sug-
gested that using a wide uniform prior distribution for the
between-studies SD increased the width of 95% CrI but did not
affect mean treatment effects. Fixed-effects models were found to
have greater statistical power than random-effects models,
although the results were otherwise similar.
1,272 
Potentially relevant publications 
identified  by electronic 
searches and hand searches
170 
Publications met the inclusion 
criteria for the systematic 
review
702 
Publications excluded based on title
400 publications excluded based on 
abstract or full text
217: Too few patients or insufficient follow-up
95: Not primary study
48: Lack of relevant outcomes
10: Wrong comparator, indication or dose
30: Not available in English
23 RCTs* met 
inclusion criteria for 
meta-analysis
13* on nucleos(t)ide-
naive HBeAg-positive 
CHB*
4* on nucleos(t)ide-
naive HBeAg-negative 
CHB*
5 on LAM-refractory 
HBeAg-positive CHB
1 on LAM-refractory 
HBeAg-negative CHB
25 RCTs identified 
through previous 
systematic reviews†
Multiple publications 
reporting the same trial
N=72
S
ys
te
m
at
ic
 r
ev
ie
w
54 RCTs excluded from meta-
analysis
46 non-RCTs met 
inclusion criteria 
for wider 
systematic review
77 RCTs* 
identified met 
inclusion criteria 
for wider 
systematic review
Figure 1 Flow diagram showing study identiﬁcation for the systematic review.Abbreviations:CHB, chronic hepatitis B;HBeAg, hepatitis B e antigen; LAM, lamivudine;
RCT, randomized controlled trial. *For the purposes of this analysis, the HBeAg-positive and HBeAg-negative subgroups of the GLOBE trial comparing LdT and LAM
[33] were counted as two separate studies. †These trials were identiﬁed by two previous systematic reviews conducted for the National Institute for Health and
Clinical Excellence (NICE) appraisal of ADV and peginterferon alpha-2a [66,67], as per our search strategy.
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All 13 trials on nucleos(t)ide-naive HBeAg-positive CHB that
met the inclusion criteria reported the proportion of patients
with HBeAg loss/seroconversion after 1 year of therapy
[3–6,8,9,18,33–38]. For HBeAg seroconversion, there was less
heterogeneity (between-studies SD: 0.315 [95% CI 0.012–1.008]
with a uniform prior [range: 0, 10]) and both ﬁxed and random-
effects models ﬁtted the data well (DIC: 158–159); this outcome
was therefore analyzed using a ﬁxed-effects meta-analysis.
This analysis found no signiﬁcant differences between nucleo-
s(t)ides in the incidence of HBeAg seroconversion, although all
treatments other than LdT plus LAM were signiﬁcantly superior
to placebo at the 0.05 level (Table 5). ADV plus LAM had the
highest probability of HBeAg seroconversion and had a 40%
probability of having the highest probability of this outcome
overall, compared with 32% for TDF, 15% for LdT, and 7% for
ETV (Table 4).
For both HBV DNA and HBeAg seroconversion, some coun-
terintuitive ﬁndings were obtained for combination therapies
because only two small RCTs evaluating nucleos(t)ide combination
therapies in treatment-naive patients met inclusion criteria [8,36].
As one trial found LdT+LAM to be nonsigniﬁcantly inferior to LdT
monotherapy for both viral suppression and HBeAg seroconver-
sion [8] and another found ADV+LAM to be nonsigniﬁcantly
inferior to LAM in terms of viral suppression [36] (P > 0.05),
similar nonsigniﬁcant trends were observed in the meta-analysis.
However, these ﬁndings for combination therapies should be inter-
preted cautiously because of the small patient numbers.
Results for Other Subgroups
Four studies met the inclusion criteria for the analysis of
nucleos(t)ide-naive patients with HBeAg-negative CHB
[10,19,33,39], although these did not form a connected network
(Fig. 2), so could not be used in isolation to estimate the efﬁcacy
of TDF relative to ETV or LdT. These four trials were each
conducted alongside a trial on patients with HBeAg-positive
nucleos(t)ide-naive CHB [3,9,18,33] that evaluated the same
treatments using identical methods and identical inclusion
criteria other than HBeAg status, viral load, and alanine ami-
notransferase (ALT) and/or the proportion of cirrhotic or
nucleos(t)ide-experienced patients enrolled.
Outcomes in each arm of the studies of HBeAg-negative
patients were compared with those in the HBeAg-positive trials
conducted alongside them in a post hoc ﬁxed-effects meta-
analysis. This suggested that the odds of achieving HBV
DNA < 300 copies/ml are 1.51 (95% CI: 1.35, 1.67) fold higher
for HBeAg-negative patients than HBeAg-positive patients, with
little variation in odds ratios between trials or treatments.
Six RCTs on nucleos(t)ide-refractory patients were identiﬁed,
which all considered LAM-refractory patients [40–49]. Three of
the six trials speciﬁcally recruited patients with mutations in the
tyrosine-methionine-aspartate-aspartate (YMDD) motif at base-
line [43,44,48], while the remainder recruited patients with
viremia despite 24 weeks of LAM therapy. Only one trial
evaluated a cohort that was predominantly HBeAg-negative
[49].
However, no RCTs meeting the inclusion criteria evaluated
either TDF or LdT in LAM-refractory patients with HBV mono-
infection, although two RCTs have evaluated TDF in LAM-
refractory patients coinfected with HIV [50,51] and an RCT
published since the search date has evaluated use of TDF in HBV
monoinfected patients who have failed ADV, of whom 57% had
previously received LAM [52]. Furthermore, 12% of the patients
participating in studies 102 and 103 had received prior therapy
A: HBeAg-positive nucleos(t)ide-naive patients
TDF
Placebo
LdT
ADV
LAM
ADV
TDF
Placebo
ETV 
(0.5 mg/day)
LdT
C: HBeAg-positive LAM-refractory patients
ETV
(1 mg/day)
LAM
ADV
ADV+ LAM
LAMADV + LAM
LdT + LAM
ETV
(0.5 mg/day)
ETV
(0.5 mg/day)
B: HBeAg-negative nucleos(t)ide-naive patients
D: HBeAg-negative LAM-refractory patients
ADV + LAM
1
4
2
1
2
1
1
1 1
1
1
11
1
1
2
2
1
1 1
LAM
2
Figure 2 Networks of evidence from the studies meeting the inclusion criteria for the meta-analysis. Each line represents one or more randomized controlled trial;
numbers indicate the number of trials informing each comparison.Abbreviations:ADV, adefovir; ETV, entecavir; HBeAg, hepatitis B e antigen; LAM, lamivudine; LdT,
telbivudine;TDF, tenofovir disoproxil fumarate.
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with LAM or emtricitabine [53]. Because there was insufﬁcient
RCT evidence to evaluate treatment effects for all nucleos(t)ides
in LAM-refractory patients with HBV mono-infection, the
results of meta-analyses on these populations are not presented
here. However, results for a secondary analysis that included HIV
coinfected patients are reported elsewhere [17].
Discussion
MTC meta-analyses found there to be a 98% probability that
TDF enables a higher proportion of patients to achieve HBV
DNA levels < 300 copies/ml at 1 year than any other licensed
nucleos(t)ide. All nucleos(t)ides signiﬁcantly increased the prob-
ability of HBeAg seroconversion by 1 year relative to placebo,
although no signiﬁcant differences in HBeAg seroconversion
were observed between nucleos(t)ides.
The systematic review demonstrated that there is currently
insufﬁcient evidence to compare the efﬁcacy of all nucleos(t)ides
in LAM-refractory patients or those with HBeAg-negative CHB.
A post hoc analysis suggested that across all treatments, the odds
of viral suppression in HBeAg-negative patients are around 1.5
times higher than in HBeAg-positive patients. However, this
ﬁnding must be interpreted with caution as it is based on com-
parisons between matched pairs of studies rather than within
RCTs, which means that the observed difference could be attrib-
utable to selection bias or confounding factors (such as baseline
viral load or ALT levels, genotype, age, or duration of infection)
rather than being a direct consequence of HBeAg status.
Although several meta-analyses have assessed the efﬁcacy of
interferons in CHB [32,54–57], our systematic review identiﬁed
only one published meta-analysis of RCTs evaluating nucleo-
s(t)ides in patients with CHB [11]. This previous study did not
Table 3 Relative treatment effects for the proportion of patients achieving HBV DNA < 300 copies/ml at 1 year
Comparison
Log-OR from random-effects
MTC (95% CrI)
Log-OR from random-effect
meta-analyses of head-to-head
trials (95% CI)
No.
trials
Placebo vs. LAM -2.25 (-3.64, -0.97)* -1.11 (-2.09, -0.13)* 1
ADV vs. LAM 0.44 (-0.56, 1.73) — 0
LdT vs. LAM 1.02 (0.24, 1.98)* 0.83 (0.58, 1.09)* 2
ETV vs. LAM 1.52 (0.80, 2.47)* 1.33 (1.09, 1.57)* 2
TDF vs. LAM 3.51 (1.88, 5.49)* — 0
LdT+LAM vs. LAM 0.62 (-0.80, 2.22) 0.70 (-0.43, 1.83) 1
ADV+LAM vs. LAM -0.08 (-1.47, 1.32) -0.09 (-0.85, 0.67) 1
ADV vs. placebo 2.69 (1.38, 4.36)* 4.41 (1.61, 7.21)* 1
LdT vs. placebo 3.27 (1.87, 4.91)* — 0
ETV vs. placebo 3.77 (2.40, 5.43)* — 0
TDF vs. placebo 5.75 (3.95, 7.99)* — 0
LdT+LAM vs. placebo 2.87 (0.99, 5.01)* — 0
ADV+LAM vs. placebo 2.17 (0.30, 4.17)* — 0
LdT vs.ADV 0.57 (-0.58, 1.63) 0.81 (-0.04, 1.66) 1
ETV vs.ADV 1.07 (-0.11, 2.17) 1.77 (0.65, 2.89)* 1
TDF vs.ADV 3.06 (1.70, 4.46)* 3.01 (2.30, 3.73)* 1
LdT+LAM vs.ADV 0.18 (-1.73, 1.93) — 0
ADV+LAM vs.ADV -0.52 (-2.46, 1.17) — 0
ETV vs. LdT 0.50 (-0.60, 1.62) — 0
TDF vs. LdT 2.49 (0.78, 4.36)* — 0
LdT+LAM vs. LdT -0.40 (-2.03, 1.20) -0.49 (-1.36, 0.37) 1
ADV+LAM vs. LdT -1.09 (-2.84, 0.47) — 0
TDF vs. ETV 1.99 (0.26, 3.85)* — 0
LdT+LAM vs. ETV -0.90 (-2.62, 0.78) — 0
ADV+LAM vs. ETV -1.60 (-3.31, -0.07)* — 0
LdT+LAM vs.TDF -2.89 (-5.25, -0.66)* — 0
ADV+LAM vs.TDF -3.58 (-6.03, -1.42)* — 0
ADV+LAM vs. LdT+LAM -0.70 (-2.82, 1.28) — 0
*P < 0.05.
ADV, adefovir; CI, conﬁdence interval; CrI, credible interval; ETV, entecavir; LAM, lamivudine; LdT, telbivudine; log-OR, natural log of the odds ratio; MTC, mixed treatment comparison;
TDF, tenofovir disoproxil fumarate.
Table 4 Proportion of patients responding to each treatment
Treatment
Proportion of patients with HBV
DNA < 300 copies/ml at 1 year
(95% CrI)
Probability of being the
best treatment for viral
suppression
Proportion of patients with
HBeAg seroconversion at 1 year
(95% CrI)
Probability of being the best
treatment for HBeAg
seroconversion
LAM 38.1% (33.7%, 42.4%) 0.0% 23.5% (16.4%, 32.1%) 1.5%
Placebo 7.2% (1.6%, 18.7%) 0.0% 10.7% (5.6%, 17.7%) 0.0%
ADV 48.9% (25.8%, 77.1%) 0.0% 22.1% (11.6%, 36.1%) 3.1%
LdT 62.5% (44.2%, 81.1%) 0.2% 25.7% (17.1%, 36.1%) 15.3%
ETV 73.0% (57.3%, 87.7%) 1.3% 23.9% (15.7%, 33.9%) 6.5%
TDF 93.8% (79.9%, 99.3%) 97.7% 26.7% (11.1%, 49.1%) 32.0%
LdT+LAM 52.9% (22.3%, 84.0%) 0.7% 13.5% (4.2%, 29.3%) 1.5%
ADV+LAM 37.4% (12.5%, 68.9%) 0.1% 28.1% (13.2%, 47.6%) 40.1%
ADV, adefovir; CrI, credible interval; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM, lamivudine; LdT, telbivudine;TDF, tenofovir disoproxil fumarate.
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TDF
Figure 3 Proportion of patients achieving unde-
tectable hepatitis B virus (HBV) DNA (<300
copies/ml) at 1 year.Abbreviations;ADV, adefovir;
ETV, entecavir; LAM, lamivudine; LdT, telbivudine;
TDF, tenofovir. Error bars represent 95% credible
intervals.
Table 5 Relative treatment effects for the proportion of patients undergoing HBeAg seroconversion by 1 year
Comparison
Log-OR from ﬁxed-effects
MTC (95% CrI)
Log-OR from ﬁxed-effect
meta-analyses of head-to-head
trials (95% CI)
No.
trials
Placebo vs. LAM -0.97 (-1.55, -0.43)* -0.94 (-1.56, -0.32)* 4
ADV vs. LAM -0.11 (-0.76, 0.53) — 0
LdT vs. LAM 0.11 (-0.19, 0.41) 0.08 (-0.23, 0.39) 2
ETV vs. LAM 0.02 (-0.28, 0.31) 0.05 (-0.25, 0.34) 2
TDF vs. LAM 0.12 (-0.82, 1.09) — 0
LdT+LAM vs. LAM -0.78 (-1.90, 0.25) -0.47 (-1.85, 0.91) 1
ADV+LAM vs. LAM 0.21 (-0.62, 1.03) 0.21 (-0.62, 1.03) 1
ADV vs. placebo 0.86 (0.23, 1.53)* 0.81 (-0.01, 1.62) 1
LdT vs. placebo 1.09 (0.48, 1.71)* — 0
ETV vs. placebo 0.99 (0.38, 1.61)* — 0
TDF vs. placebo 1.10 (0.16, 2.08)* — 0
LdT+LAM vs. placebo 0.20 (-1.04, 1.36) — 0
ADV+LAM vs. placebo 1.18 (0.19, 2.18)* — 0
LdT vs.ADV 0.22 (-0.43, 0.88) 0.51 (-0.49, 1.50) 1
ETV vs.ADV 0.12 (-0.54, 0.81) -0.45 (-1.72, 0.82) 1
TDF vs.ADV 0.23 (-0.45, 0.96) 0.22 (-0.48, 0.92) 1
LdT+LAM vs.ADV -0.67 (-1.92, 0.53) — 0
ADV+LAM vs.ADV 0.31 (-0.74, 1.37) — 0
ETV vs. LdT -0.10 (-0.51, 0.32) — 0
TDF vs. LdT 0.01 (-0.95, 0.99) — 0
LdT+LAM vs. LdT -0.89 (-1.99, 0.12) -0.93 (-2.00, 0.13) 1
ADV+LAM vs. LdT 0.09 (-0.79, 0.98) — 0
TDF vs. ETV 0.11 (-0.86, 1.1) — 0
LdT+LAM vs. ETV -0.79 (-1.95, 0.27) — 0
ADV+LAM vs. ETV 0.19 (-0.70, 1.07) — 0
LdT+LAM vs.TDF -0.90 (-2.35, 0.48) — 0
ADV+LAM vs.TDF 0.08 (-1.19, 1.34) — 0
ADV+LAM vs. LdT+LAM 0.98 (-0.35, 2.37) — 0
*P < 0.05 level.
ADV, adefovir; CI, conﬁdence interval; CrI, credible interval; ETV, entecavir; LAM, lamivudine; LdT, telbivudine; MTC, mixed treatment comparison; log-OR, natural log of the odds ratio;
TDF, tenofovir disoproxil fumarate.
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include TDF. For the other nucleos(t)ides, it reported similar
results, but suggested that LAM was signiﬁcantly superior to
ADV, whereas we observed a nonsigniﬁcant trend toward infe-
riority. The previous analysis does not appear to have been based
on relative treatment effects and may therefore be prone to bias
because of differences between studies.
In the current analysis, the efﬁcacy of each treatment was
calculated using the relative treatment effects from individual
trials and was based on recognized statistical methods for con-
ducting indirect comparisons with minimal bias and preserving
the randomization within each RCT [23,24]. Because the analy-
sis was based on measures of relative efﬁcacy and makes adjust-
ments to allow for inconsistency between trials, the meta-analysis
estimates of the proportion of patients responding to treatment
(Table 4) do not necessarily match those observed in clinical
trials, but are based on unbiased estimates of differences between
treatments. By contrast, “naive” indirect comparisons (whereby
the outcomes for each treatment are based on the average of the
outcomes observed in the arms of separate studies in which that
treatment was used) ignore the randomization within each RCT
and have been shown to be prone to bias and to underestimate
the degree of uncertainty around the averages outcome for each
treatment [24].
However, although conducting indirect comparisons based
on the relative treatment effects observed in each trial minimizes
the risk of bias, the treatment effects observed in trials may differ
from the true treatment effects by chance. This is particularly true
for the comparison between TDF and ADV, which is based on a
single study (103) in which only 12% (11/90) of ADV-treated
patients achieved HBV DNA < 300 copies/ml [9,21]. It is pos-
sible that the log-OR for TDF relative to ADV that was observed
in Study 103 may, by chance, be higher than the true difference
between these drugs; if this is the case, repeating our meta-
analysis in the future with more data may yield a lower estimate
of the probability of responding to TDF. However, since Study
103 used appropriate methods for randomization and blinding,
the treatment effect it observed is unlikely to systematically differ
from the true treatment effect and is therefore unlikely to have
introduced any bias into the meta-analysis.
Interferon-alpha and peginterferon-alpha were excluded from
this analysis as they are generally given as ﬁrst-line therapy to
patients who have a particularly high chance of responding to
and tolerating treatment and as the outcome of interferon
therapy is most appropriately assessed 24 weeks after end of
treatment. Including interferons would have increased the
amount of data available, but would also have greatly increased
the complexity and/or heterogeneity within the analysis due to
the wide array of formulations and dosing schedules. Further-
more, because peginterferon-alpha has been found to produce a
lower probability of HBV DNA < 400 copies/ml than LAM
immediately after a 48-week course of treatment [20], it is likely
that interferons would have been found to be less effective than
TDF and other newer nucleos(t)ides.
Although MTC could also be used for outcomes such as ALT
normalization or histological improvement, it was not possible to
conduct meta-analyses of less common outcomes, such as hepa-
titis B surface antigen (HBsAg) seroconversion or the incidence
or progression of cirrhosis, because few RCTs reported such
outcomes.
The analysis suggested that there was a substantial degree of
heterogeneity in the effect of treatment on viral suppression. The
observed heterogeneity may be due to factors that differed
between studies, such as viral load, age, HBV genotype, ALT, or
the duration or mode of infection. In principle, such heterogene-
ity could be explored through meta-regression; however, the
limited number of trials and relatively large number of treat-
ments within the evidence network means that such analyses
would have had limited power to detect the effect of
covariates—particularly for variables that are not reported by all
trials.
As with all meta-analyses, the subset of trials available for
analysis may be affected by publication bias; however, this
cannot be assessed at present, as methods for identifying publi-
cation bias in MTC have not yet been developed. Imputation of
missing data helped to minimize bias by allowing us to include all
potentially-relevant data in the analysis, although one limitation
of the imputation methods we used is that they did not enable the
uncertainty around imputed values to be taken into account
in the MTC. Because missing data affects meta-analyses in all
disease areas, further work is required to develop and make
recommendations on the appropriate methods for imputing
missing values in MTC.
The systematic review highlighted a paucity of studies evalu-
ating nucleos(t)ide combinations. Because ADV+LAM and
LdT+LAM are each supported by just one small RCT in HBeAg-
positive nucleos(t)ide-naive patients, outcomes for these treat-
ments must be interpreted with caution. Furthermore, there is a
need for more studies on HBeAg-negative patients and for trials
evaluating TDF and LdT in patients who are resistant to LAM or
other nucleos(t)ides. Additional studies comparing treatments for
HBeAg-positive treatment-naive CHB would also enable future
meta-analyses to provide more accurate estimates of treatment
effects. We conducted further literature searches in March 2010
to identify whether any additional trials have been published
since the search date for the systematic review (August 2007);
these identiﬁed only two studies that would have met our inclu-
sion criteria [58,59], which are highly unlikely to have changed
the conclusions of the analysis as one [58] was very small
(n < 50) and the other [59] observed similar results to the study
by Lai et al. [8].
Based on the RCT evidence currently available, this analysis
ﬁnds that among licensed nucleosides, TDF has the highest prob-
ability of achieving viral suppression at 1 year. In addition to
short-term potency, it is necessary to take account of the drug
resistance proﬁle, incidence of HBsAg seroconversion, durability
of response, and cost of each treatment when deciding on the
optimal treatment for CHB. The results of MTC can be readily
used alongside information on these other factors within
decision-analytical models that assess cost-effectiveness, because
MTC allows the relative efﬁcacy of multiple treatments to be
evaluated in the same analysis and enables direct estimation of
transition probabilities. The accompanying article [17] uses the
results of this meta-analysis and other evidence sources, taking
into account differences in cost and resistance rates as well as
long-term efﬁcacy, and ﬁnds ﬁrst-line TDF to be the most cost-
effective treatment for CHB in a UK setting. The evidence on the
efﬁcacy, safety, and cost-effectiveness of TDF has recently been
reviewed by NICE, who have recommended TDF for use in
England and Wales within its license indication [60].
Conclusions
In conclusion, this meta-analysis demonstrates that in HBeAg-
positive nucleos(t)ide-naive patients, TDF has a higher probabil-
ity of achieving undetectable HBV DNA at 1 year than any other
nucleos(t)ide currently licensed for CHB in the UK. The prob-
ability of HBeAg seroconversion was not found to differ signiﬁ-
cantly between nucleos(t)ides. More trials on nucleos(t)ide
combinations, HBeAg-negative CHB and patients resistant to
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one or more nucleos(t)ides are required to assess the beneﬁts
of combination therapy and evaluate relative efﬁcacy in other
populations.
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